The JAK2 V617F mutation is found in patients with blood-related diseases such as polycythemia vera, essential thrombocythemia and myelofibrosis. Ruxolitinib is effective as a JAK inhibitor, making it a prognostic factor in determining drug response. Detection of the JAK2 V617F mutation facilitates the classification of patients with MPD (myeloproliferative disease) into three levels of diagnostic certainty (possible, probable and definitive) and to determine which signal transduction therapy is appropriate for each patient. In addition, the WHO (World Health Organization) has recommended JAK2 V617F mutation testing as a clinical trial.
PNAClamp™ Mutation Detection Kit JAK2
For the detection of JAK2 mutations in tissue biopsies
Cat. No. PNAC-6001
Other products
Microcentrifuge tubes with SureSeal ™ screw caps
SureSeal™ sterile screw-capped microtubes come in a variety of sizes,...
PANAMutyper™ R NRAS
For detection of NRAS mutations in tissue biopsies Cat. No....
SMOChem. dUTP Solution – Sodium Salt (100 mM)
Use instead of dTTP in PCR and RT-PCR protocols to...
9K Series Plasmid Miniprep Kit – 9K-006-0010
Plasmid purification kit: the Bio Basic Plasmid DNA extraction kit...